Shares react to regulator decision
Gain Therapeutics Inc (NASDAQ:GANX) experienced a notable after-hours share increase on Monday after the Food and Drug Administration granted clearance for the company’s Investigational New Drug application for GT-02287, a candidate for the treatment of Parkinson’s disease. The company’s stock rose 21.2% in after-hours trading following the announcement.
What the IND clearance allows
The FDA authorization enables Gain to move forward with a Phase 2 clinical program for GT-02287 in the United States. The company indicated the Phase 2a trial is expected to begin during the third quarter of 2026. The regulator’s decision follows Phase 1 data that the company characterized as demonstrating both biomarker and clinical evidence of activity, together with favorable safety and tolerability findings.
About GT-02287
GT-02287 is an orally administered, brain-penetrant small molecule designed to restore the function of the lysosomal enzyme glucocerebrosidase. The development program targets Parkinson’s disease broadly - including patients with or without a GBA1 mutation.
Planned trial scope and prior studies
The planned Phase 2a study will enroll participants across sites in the United States, Australia, and Europe. Both the Phase 1a and Phase 1b studies were conducted in Australia, and Australian centers are expected to continue participating in the Phase 2 trial alongside new U.S. and European sites.
In the Phase 1b extension, all 16 participants remained on study at Day 150. Biomarker analyses in that extension showed an average 81% reduction in cerebrospinal fluid glucosylsphingosine after 90 days among participants who had elevated baseline levels. The same subgroup with elevated baseline CSF GluSph demonstrated greater improvement in MDS-UPDRS Part II and Part III scores at Day 150 compared with participants who had low baseline GluSph.
Program significance
GT-02287 is the first allosteric modulator originating from Gain’s Magellan AI drug discovery platform to receive IND clearance. The FDA action clears the path for the company to expand clinical testing into a later, multi-regional phase.
Context on disease burden
Parkinson’s disease affects more than 1.1 million people in the United States, with nearly 90,000 new diagnoses each year. According to the information provided, there are currently no approved therapies that halt or reverse disease progression.